Michael Alexanian

2.2k total citations
18 papers, 1.2k citations indexed

About

Michael Alexanian is a scholar working on Molecular Biology, Cancer Research and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Michael Alexanian has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Cancer Research and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Michael Alexanian's work include Cancer-related molecular mechanisms research (8 papers), RNA modifications and cancer (7 papers) and RNA Research and Splicing (6 papers). Michael Alexanian is often cited by papers focused on Cancer-related molecular mechanisms research (8 papers), RNA modifications and cancer (7 papers) and RNA Research and Splicing (6 papers). Michael Alexanian collaborates with scholars based in United States, Switzerland and Spain. Michael Alexanian's co-authors include Samir Ounzain, Thierry Pedrazzini, Blanche Schroen, Rudi Micheletti, Mohamed Nemir, Alexandre Sarre, Isabelle Plaisance, Rory Johnson, Stéphane Heymans and Roderic Guigó and has published in prestigious journals such as Circulation, Nature Communications and Circulation Research.

In The Last Decade

Michael Alexanian

18 papers receiving 1.2k citations

Peers

Michael Alexanian

CCM

SURGE

ONCOL

Monika M Gladka Netherlands

Rudy F. Duisters Netherlands

Zenia Tiang Singapore

Zhan-Peng Huang China

Robert A. McDonald United Kingdom

Patima Sdek United States

Banu Eskiocak United States

Brian N. Bourke United States

Marjorie Perron Canada

Calvin T. Hang United States

Monika M Gladka Netherlands

Michael Alexanian

814 ×0.8

454 ×0.7

323 ×1.3

CCM

108 ×0.7

SURGE

56 ×0.7

ONCOL

Citations per year, relative to Michael Alexanian Michael Alexanian (= 1×) peers Monika M Gladka

Countries citing papers authored by Michael Alexanian

Since Specialization

Citations

This map shows the geographic impact of Michael Alexanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Alexanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Alexanian more than expected).

Fields of papers citing papers by Michael Alexanian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Alexanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Alexanian. The network helps show where Michael Alexanian may publish in the future.

Co-authorship network of co-authors of Michael Alexanian

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Alexanian. A scholar is included among the top collaborators of Michael Alexanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Alexanian. Michael Alexanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Schuetze, Katherine B., Matthew S. Stratton, Rushita A. Bagchi, et al.. (2024). BRD4 inhibition rewires cardiac macrophages toward a protective phenotype marked by low MHC class II expression. American Journal of Physiology-Heart and Circulatory Physiology. 328(2). H294–H309. 2 indexed citations

Nishino, Tomohiro, Sanjeev S. Ranade, Angelo Pelonero, et al.. (2023). Single-cell multimodal analyses reveal epigenomic and transcriptomic basis for birth defects in maternal diabetes. Nature Cardiovascular Research. 2(12). 1190–1203. 5 indexed citations

Hsu, Austin, Qiming Duan, Daniel S. Day, et al.. (2022). Targeting transcription in heart failure via CDK7/12/13 inhibition. Nature Communications. 13(1). 4345–4345. 8 indexed citations

Jiang, Zhen, Qiming Duan, Edward L. LaGory, et al.. (2022). KLF15 cistromes reveal a hepatocyte pathway governing plasma corticosteroid transport and systemic inflammation. Science Advances. 8(10). eabj2917–eabj2917. 18 indexed citations

Micheletti, Rudi & Michael Alexanian. (2022). Transcriptional plasticity of fibroblasts in heart disease. Biochemical Society Transactions. 50(5). 1247–1255. 4 indexed citations

Joy, David, M. Ariel Kauss, Vaishaali Natarajan, et al.. (2021). Co-emergence of cardiac and gut tissues promotes cardiomyocyte maturation within human iPSC-derived organoids. Cell stem cell. 28(12). 2137–2152.e6. 98 indexed citations

Padmanabhan, Arun, Michael Alexanian, Ricardo Linares-Saldana, et al.. (2020). BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes. Circulation. 142(24). 2338–2355. 32 indexed citations

Xu, Jun, Michael Alexanian, Gaia Andreoletti, et al.. (2020). Conserved Epigenetic Regulatory Logic Infers Genes Governing Cell Identity. Cell Systems. 11(6). 625–639.e13. 24 indexed citations

Alexanian, Michael & Samir Ounzain. (2020). Long Noncoding RNAs in Cardiac Development. Cold Spring Harbor Perspectives in Biology. 12(11). a037374–a037374. 7 indexed citations

10.

Stratton, Matthew S., Rushita A. Bagchi, Marina Barreto Felisbino, et al.. (2019). Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. Circulation Research. 125(7). 662–677. 123 indexed citations

11.

Alexanian, Michael, Arun Padmanabhan, Timothy A. McKinsey, & Saptarsi M. Haldar. (2019). Epigenetic therapies in heart failure. Journal of Molecular and Cellular Cardiology. 130. 197–204. 18 indexed citations

12.

Micheletti, Rudi, Isabelle Plaisance, Brian J. Abraham, et al.. (2017). The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Science Translational Medicine. 9(395). 249 indexed citations

13.

Micheletti, Rudi, Isabelle Plaisance, Brian J. Abraham, et al.. (2017). The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. DSpace@MIT (Massachusetts Institute of Technology). 24 indexed citations

14.

Alexanian, Michael, Thierry Pedrazzini, & Samir Ounzain. (2017). New Lncs to mesendoderm specification. Journal of Thoracic Disease. 9(S1). S5–S8. 1 indexed citations

15.

Alexanian, Michael, Marco Mina, Clayton E. Friedman, et al.. (2017). A transcribed enhancer dictates mesendoderm specification in pluripotency. Nature Communications. 8(1). 1806–1806. 47 indexed citations

16.

Ounzain, Samir, Rudi Micheletti, Carme Arnan, et al.. (2015). CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. Journal of Molecular and Cellular Cardiology. 89(Pt A). 98–112. 208 indexed citations

17.

Ounzain, Samir, Rudi Micheletti, Frédéric Burdet, et al.. (2014). Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease. Journal of Molecular and Cellular Cardiology. 76. 55–70. 96 indexed citations

18.

Ounzain, Samir, R. Micheletti, Tim Beckmann, et al.. (2014). Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. European Heart Journal. 36(6). 353–368. 214 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact